{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:37:15Z","timestamp":1790797035876,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier","isbn-type":[{"value":"9780443295485","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.vh.2024.11.001","type":"book-chapter","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T15:59:50Z","timestamp":1731686390000},"page":"185-202","source":"Crossref","is-referenced-by-count":6,"title":["Hypogonadism in men with prolactinoma: Diagnosis, treatment, and management of persistent hypogonadism"],"prefix":"10.1016","member":"78","reference":[{"issue":"4","key":"10.1016\/bs.vh.2024.11.001_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12041437","article-title":"The role of aromatase inhibitors in male prolactinoma","volume":"12","author":"Akirov","year":"2023","journal-title":"Journal of Clinical Medicine"},{"key":"10.1016\/bs.vh.2024.11.001_bib2","doi-asserted-by":"crossref","DOI":"10.1007\/s11102-022-01242-y","article-title":"Proportion and predictors of Hypogonadism Recovery in Men with Macroprolactinomas treated with dopamine agonists","author":"Al Dahmani","year":"2022","journal-title":"Pituitary"},{"key":"10.1016\/bs.vh.2024.11.001_bib3","article-title":"Prevalence of hyperprolactinemia and clinically apparent prolactinomas in men undergoing fertility evaluation","author":"Ambulkar","year":"2021","journal-title":"Urology"},{"issue":"1","key":"10.1016\/bs.vh.2024.11.001_bib4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000371851","article-title":"Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas","volume":"101","author":"Auriemma","year":"2015","journal-title":"Neuroendocrinology"},{"issue":"9","key":"10.1016\/bs.vh.2024.11.001_bib5","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1210\/clinem\/dgad174","article-title":"Approach to the patient with prolactinoma","volume":"108","author":"Auriemma","year":"2023","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"1","key":"10.1016\/bs.vh.2024.11.001_bib6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.fertnstert.2005.01.102","article-title":"Pituitary imaging is indicated for the evaluation of hyperprolactinemia","volume":"84","author":"Bayrak","year":"2005","journal-title":"Fertility and Sterility"},{"issue":"6","key":"10.1016\/bs.vh.2024.11.001_bib7","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41574-019-0194-6","article-title":"Prolactin \u2013 A pleiotropic factor in health and disease","volume":"15","author":"Bernard","year":"2019","journal-title":"Nature Reviews. Endocrinology"},{"issue":"5","key":"10.1016\/bs.vh.2024.11.001_bib8","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1210\/jc.2018-00229","article-title":"Testosterone therapy in men with hypogonadism: An endocrine society clinical practice guideline","volume":"103","author":"Bhasin","year":"2018","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"24","key":"10.1016\/bs.vh.2024.11.001_bib9","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.2174\/1381612826666200523175806","article-title":"Gonadotropin treatment for the male hypogonadotropic hypogonadism","volume":"27","author":"Boeri","year":"2021","journal-title":"Current Pharmaceutical Design"},{"issue":"3","key":"10.1016\/bs.vh.2024.11.001_bib10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11102-024-01392-1","article-title":"Quality of life in prolactinoma: A systematic review","volume":"27","author":"Castle-Kirszbaum","year":"2024","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/bs.vh.2024.11.001_bib11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/eje.0.1480325","article-title":"Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia","volume":"148","author":"Colao","year":"2003","journal-title":"European Journal of Endocrinology"},{"issue":"4","key":"10.1016\/bs.vh.2024.11.001_bib12","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1210\/jc.2003-030979","article-title":"Outcome of cabergoline treatment in men with prolactinoma: Effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis","volume":"89","author":"Colao","year":"2004","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"5","key":"10.1016\/bs.vh.2024.11.001_bib13","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s11102-024-01445-5","article-title":"Recovery from hypogonadism in men with prolactinoma treated with dopamine agonists","volume":"27","author":"Constantinescu","year":"2024","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/bs.vh.2024.11.001_bib14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ecl.2020.04.002","article-title":"The epidemiology of pituitary adenomas","volume":"49","author":"Daly","year":"2020","journal-title":"Endocrinology and Metabolism Clinics of North America"},{"issue":"3","key":"10.1016\/bs.vh.2024.11.001_bib15","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1530\/eje.0.1380286","article-title":"Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: A comparison with bromocriptine","volume":"138","author":"De Rosa","year":"1998","journal-title":"European Journal of Endocrinology"},{"issue":"3","key":"10.1016\/bs.vh.2024.11.001_bib16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2265.2006.02461.x","article-title":"The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males","volume":"64","author":"De Rosa","year":"2006","journal-title":"Clinical Endocrinology"},{"issue":"7","key":"10.1016\/bs.vh.2024.11.001_bib17","first-page":"2102","article-title":"Sex-related difference in the growth of prolactinomas: A clinical and proliferation marker study","volume":"82","author":"Delgrange","year":"1997","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"5","key":"10.1016\/bs.vh.2024.11.001_bib18","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1530\/EJE-09-0012","article-title":"Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: A study in 122 patients","volume":"160","author":"Delgrange","year":"2009","journal-title":"European Journal of Endocrinology"},{"issue":"5","key":"10.1016\/bs.vh.2024.11.001_bib19","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1507\/endocrj1954.31.651","article-title":"Restoration of fertility with gonadotropin and bromocriptine in a hypogonadal man after removal of macroprolactinoma","volume":"31","author":"Demura","year":"1984","journal-title":"Endocrinologia Japonica"},{"issue":"1","key":"10.1016\/bs.vh.2024.11.001_bib20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11102-019-01009-y","article-title":"Prolactinomas in males: Any differences?","volume":"23","author":"Duskin-Bitan","year":"2020","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/bs.vh.2024.11.001_bib21","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/cncr.20412","article-title":"The prevalence of pituitary adenomas: A systematic review","volume":"101","author":"Ezzat","year":"2004","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/bs.vh.2024.11.001_bib22","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1210\/jc.2002-020426","article-title":"The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma","volume":"87","author":"Gillam","year":"2002","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"4","key":"10.1016\/bs.vh.2024.11.001_bib23","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1210\/er.2017-00025","article-title":"A reappraisal of testosterone\u2019s binding in circulation: Physiological and clinical implications","volume":"38","author":"Goldman","year":"2017","journal-title":"Endocrine Reviews"},{"key":"10.1016\/bs.vh.2024.11.001_bib24","doi-asserted-by":"crossref","DOI":"10.5534\/wjmh.221027","article-title":"The British Society for sexual medicine guidelines on male adult testosterone deficiency, with statements for practice","author":"Hackett","year":"2023","journal-title":"The World Journal of Men\u2019s Health"},{"issue":"4","key":"10.1016\/bs.vh.2024.11.001_bib25","doi-asserted-by":"crossref","first-page":"669","DOI":"10.4158\/EP10026.CR","article-title":"Achievement of fertility in an infertile man with resistant macroprolactinoma using high-dose bromocriptine and a combination of human chorionic gonadotropin and an aromatase inhibitor","volume":"16","author":"Heidari","year":"2010","journal-title":"Endocrine Practice"},{"issue":"12","key":"10.1016\/bs.vh.2024.11.001_bib26","doi-asserted-by":"crossref","first-page":"e1506","DOI":"10.1210\/clinem\/dgad393","article-title":"Long-term follow-up of 84 patients with giant prolactinomas\u2014A Swedish nationwide study","volume":"108","author":"Himonakos","year":"2023","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"issue":"3","key":"10.1016\/bs.vh.2024.11.001_bib27","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/andr.13146","article-title":"Clomiphene citrate for men with hypogonadism: A systematic review and meta-analysis","volume":"10","author":"Huijben","year":"2022","journal-title":"Andrology"},{"issue":"4","key":"10.1016\/bs.vh.2024.11.001_bib28","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11102-020-01045-z","article-title":"Axis-specific analysis and predictors of endocrine recovery and deficits for non-functioning pituitary adenomas undergoing endoscopic transsphenoidal surgery","volume":"23","author":"Hwang","year":"2020","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/bs.vh.2024.11.001_bib29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/cen.12124","article-title":"Does hypopituitarism recover when macroprolactinomas are treated with cabergoline?","volume":"79","author":"Karavitaki","year":"2013","journal-title":"Clinical Endocrinology"},{"issue":"1","key":"10.1016\/bs.vh.2024.11.001_bib30","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11102-019-01000-7","article-title":"Aggressive prolactinomas: How to manage?","volume":"23","author":"Lasolle","year":"2020","journal-title":"Pituitary"},{"issue":"5","key":"10.1016\/bs.vh.2024.11.001_bib31","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s11102-023-01337-0","article-title":"Giant prolactinomas, a detailed analysis of 196 adult cases","volume":"26","author":"Lisa","year":"2023","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/bs.vh.2024.11.001_bib32","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2265.1979.tb03067.x","article-title":"Hyperprolactinaemia and hypogonadism in men: Response to exogenous gonadotrophins","volume":"11","author":"Luboshitzky","year":"1979","journal-title":"Clinical Endocrinology"},{"issue":"1","key":"10.1016\/bs.vh.2024.11.001_bib33","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000495775","article-title":"Management of dopamine agonist-resistant prolactinoma","volume":"109","author":"Maiter","year":"2019","journal-title":"Neuroendocrinology"},{"issue":"2","key":"10.1016\/bs.vh.2024.11.001_bib34","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"1","key":"10.1016\/bs.vh.2024.11.001_bib35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/BF03345523","article-title":"Prevalence of osteopenia in men with prolactinoma","volume":"28","author":"Naliato","year":"2005","journal-title":"Journal of Endocrinological Investigation"},{"key":"10.1016\/bs.vh.2024.11.001_bib36","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.clineuro.2016.01.029","article-title":"Hypopituitarism patterns among adult males with prolactinomas","volume":"144","author":"Peng","year":"2016","journal-title":"Clinical Neurology and Neurosurgery"},{"issue":"12","key":"10.1016\/bs.vh.2024.11.001_bib37","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: A Pituitary Society international Consensus Statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nature Reviews. Endocrinology"},{"issue":"9","key":"10.1016\/bs.vh.2024.11.001_bib38","first-page":"3053","article-title":"Primary medical therapy of micro- and macroprolactinomas in men","volume":"85","author":"Pinzone","year":"2000","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"4","key":"10.1016\/bs.vh.2024.11.001_bib39","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1055\/a-0859-1144","article-title":"Unveiling the role of prolactin and its receptor in male reproduction","volume":"51","author":"Raut","year":"2019","journal-title":"Hormone and Metabolic Research"},{"issue":"1","key":"10.1016\/bs.vh.2024.11.001_bib40","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1530\/EJE-09-0084","article-title":"Recovery of persistent hypogonadism by clomiphene in males with prolactinomas under dopamine agonist treatment","volume":"161","author":"Ribeiro","year":"2009","journal-title":"European Journal of Endocrinology"},{"issue":"4","key":"10.1016\/bs.vh.2024.11.001_bib41","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/cen.14541","article-title":"Long-term response to cabergoline and multi-modal treatment in men with macroprolactinoma: Does size really matter?","volume":"95","author":"Rudman","year":"2021","journal-title":"Clinical Endocrinology"},{"issue":"6","key":"10.1016\/bs.vh.2024.11.001_bib42","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1007\/s11102-022-01259-3","article-title":"Predicting hypogonadotropic hypogonadism persistence in male macroprolactinoma","volume":"25","author":"Rudman","year":"2022","journal-title":"Pituitary"},{"issue":"7","key":"10.1016\/bs.vh.2024.11.001_bib43","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/andr.13428","article-title":"Hemoglobin decline as a signal for hyperprolactinemia onset prior to prolactinoma diagnosis in hypogonadal men","volume":"11","author":"Rudman","year":"2023","journal-title":"Andrology"},{"issue":"12","key":"10.1016\/bs.vh.2024.11.001_bib44","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa650","article-title":"Predictors of chronic LH-testosterone axis suppression in male macroprolactinomas with normoprolactinemia on cabergoline","volume":"105","author":"Sehemby","year":"2020","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"8","key":"10.1016\/bs.vh.2024.11.001_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.arcmed.2023.102883","article-title":"Prolactinomas resistant to dopamine agonists: Pathophysiology and treatment","volume":"54","author":"Shimon","year":"2023","journal-title":"Archives of Medical Research"},{"issue":"3","key":"10.1016\/bs.vh.2024.11.001_bib46","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1007\/s11102-013-0497-x","article-title":"Male prolactinomas presenting with normal testosterone levels","volume":"17","author":"Shimon","year":"2014","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/bs.vh.2024.11.001_bib47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11102-010-0251-6","article-title":"Anemia in a cohort of men with macroprolactinomas: Increase in hemoglobin levels follows prolactin suppression","volume":"14","author":"Shimon","year":"2011","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/bs.vh.2024.11.001_bib48","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1023\/A:1025377816769","article-title":"Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function","volume":"5","author":"Sibal","year":"2002","journal-title":"Pituitary"},{"key":"10.1016\/bs.vh.2024.11.001_bib49","doi-asserted-by":"crossref","DOI":"10.1007\/s12020-024-03817-0","article-title":"Long-term use of clomiphene in male macroprolactinomas with persistent hypogonadism","author":"Stumpf","year":"2024","journal-title":"Endocrine"},{"issue":"2","key":"10.1016\/bs.vh.2024.11.001_bib50","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11102-023-01313-8","article-title":"How to manage intolerance to dopamine agonist in patients with prolactinoma","volume":"26","author":"Stumpf","year":"2023","journal-title":"Pituitary"},{"key":"10.1016\/bs.vh.2024.11.001_bib51","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/756069","article-title":"Clinical characteristics and treatment outcome of 485 patients with nonfunctioning pituitary macroadenomas","volume":"2015","author":"Vargas","year":"2015","journal-title":"International Journal of Endocrinology"},{"issue":"7","key":"10.1016\/bs.vh.2024.11.001_bib52","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","article-title":"Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients","volume":"84","author":"Verhelst","year":"1999","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/bs.vh.2024.11.001_bib53","article-title":"Recovery of male hypogonadism following successful treatment of prolactinoma: The experience of an integrated health network","author":"Voica","year":"2021","journal-title":"Journal of the Endocrine \u2026"},{"issue":"Supplement_1","key":"10.1016\/bs.vh.2024.11.001_bib54","doi-asserted-by":"crossref","first-page":"A632","DOI":"10.1210\/jendso\/bvab048.1289","article-title":"Recovery of male hypogonadism following successful treatment of prolactinoma: The experience of an integrated health network","volume":"5","author":"Voica","year":"2021","journal-title":"Journal of the Endocrine Society"},{"issue":"6","key":"10.1016\/bs.vh.2024.11.001_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci12060796","article-title":"Hypogonadism in male patients with pituitary adenoma and its related mechanism: A review of literature","volume":"12","author":"Yan","year":"2022","journal-title":"Brain Sciences"}],"container-title":["Vitamins and Hormones","Hormones and Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0083672924000803?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0083672924000803?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T16:24:56Z","timestamp":1755015896000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0083672924000803"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443295485"],"references-count":55,"URL":"https:\/\/doi.org\/10.1016\/bs.vh.2024.11.001","relation":{},"ISSN":["0083-6729"],"issn-type":[{"value":"0083-6729","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}